
Most-Read Articles From AJMC's Conference Coverage in 2015
Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.
Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.
10. Ketamine and More: What's the Status of Antidepressants?
9. Oncologist Highlights Primary Reasons for the High Cost of Cancer Care
At a meeting hosted by the Community Oncology Alliance (COA), “Community Oncology 2.0, Moving Forward on Payment Reform,” COA’s past president David Eagle, MD, partner at Lake Norman Oncology,
8. Telehealth Offers Effective Way to Treat Veterans for PTSD
Presenters at the US Psychiatric and Mental Health Congress in San Diego,
7. Two Diet Studies, Two Approaches to Finding Keys to Weight Loss, Reduced Risk Factors
During a session entitled, “Concepts in Nutrition and Diabetes Prevention and Treatment,” at the 75th Scientific Sessions of the American Diabetes Association in Boston, back-to-back presentations offered 2 very different studies, each asking the question: which type of diet will not only help at-risk patients lose weight, but keep impaired glucose tolerance at bay? While 1 study found that preserving lean body mass was more important than overall weight loss, the other emphasized long-term metabolic control in type 2 diabetes patients.
6. Moving to the Future of Healthcare: Value-Based Models
During his
5. ELIXA Trial Results Find No Cardiac Risk, Benefit for Lixisenatide
GLP-1 agonists present no risks or benefits for patients with type 2 diabetes who take lixisenatide,
4. Key Specialty Pharmaceutical Market Trends
At the 27th annual meeting of the Academy of Managed Care Pharmacy in San Diego, Aimee Tharaldson, PharmD, senior clinical consultant in emerging therapeutics at Express Scripts,
3. Cholesterol-Fighting Drug Evolocumab Also Reduces Cardiovascular Events, Study Finds
With a raging battle over the development of PCSK9 inhibitors to treat familial hypercholesterolemia, everyone in the healthcare world had focused their attention on whether Amgen or Regeneron would hit the market first. At the American College of Cardiology meeting in San Diego, Amgen's PCSK9 inhibitor, evolocumab,
2. Human Nature Limits Good Medication Adherence in Bipolar Patients, Jamison Says
Kay Redfield Jamison, PhD, professor of psychiatry at Johns Hopkins School of Medicine,
1. PROMISE Results Have Implications for Managed Care; May Change Guidelines and Put Pressure on Payers to Cover CTA
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.